TaiMed Biologics, Inc.
Industry Group: Pharmaceuticals
Country/Region: Taiwan
Identifier: ROCO:4147
TaiMed Biologics Inc is a Taiwan-based biotechnology company. It is engaged in the discovery, development, and delivery of medicines for infectious disease. It capitalizes on its intellectual, extensive expertise, and management resources to develop a health-care product pipeline that benefits patients, rewards investors, and propels to prominence in the biotechnology industry. The company's products pipeline includes TMB-365, VRC07-523LS, and others.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 366 out of 920
Universe
Global Universe 9737 out of 16093
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Pliant Therapeutics, Inc. |
25.3
Medium
|
226 out of 920 |
PureTech Health Plc |
26.6
Medium
|
303 out of 920 |
Aurinia Pharmaceuticals, Inc. |
27.3
Medium
|
351 out of 920 |
TaiMed Biologics, Inc. |
27.4
Medium
|
366 out of 920 |
Disc Medicine, Inc. |
30.1
High
|
537 out of 920 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
TaiMed Biologics, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
TaiMed Biologics, Inc.'s Management of ESG Material Risk is Average